SCHEMBL3345878

SCHEMBL3345878

Cn1c(C(N)=O)cc2[c]cccc2c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.37
SRC P12931 1/20 0.37
NPC1 O15118 3/20 0.34
KDM4E B2RXH2 5/20 0.33
ALDH1A1 P00352 4/20 0.33
HSD17B10 Q99714 3/20 0.33
HPGD P15428 2/20 0.33
SLC9A1 P19634 2/20 0.33
TSHR P16473 2/20 0.33
MAPK1 P28482 2/20 0.33
MAPT P10636 2/20 0.33
LMNA P02545 1/20 0.33
BRD4 O60885 1/20 0.33
BRPF1 P55201 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33
CREBBP Q92793 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799169 0.81 SLC9A1 (0.43) EGFRSRCNPC1KDM4EALDH1A1
SCHEMBL3586201 0.81 SLC9A1 (0.38) NPC1KDM4EALDH1A1HSD17B10SLC9A1
SCHEMBL3347472 0.80 NPC1 (0.36) NPC1ALDH1A1HPGDTSHRMAPT
SCHEMBL3580573 0.79 NPC1 (0.31) EGFRSRCNPC1HPGDLMNA
SCHEMBL3341721 0.78 KDM4E (0.33) EGFRSRCKDM4EALDH1A1HSD17B10
SCHEMBL3589089 0.77 NPC1 (0.30) NPC1
SCHEMBL3584822 0.77 PIK3CA (0.38) NPC1TSHRMAPT
SCHEMBL3576486 0.77 SMN1; SMN2 (0.36) NPC1KDM4EALDH1A1HSD17B10TSHR
SCHEMBL4994314 0.76 PLA2G10 (0.45) SRCKDM4EALDH1A1HPGDMAPT
SCHEMBL3582637 0.71 NPC1 (0.34) NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372865-B2 Dihydropyridone amides as P2X7 modulators ROCHE PALO ALTO LLC (US) 2013-02-12 US claimed
US-8435990-B2 Dihydropyrimidone amides as P2X7 modulators ROCHE PALO ALTO LLC (US) 2013-05-07 US disclosed
US-8372865-B2 Dihydropyridone amides as P2X7 modulators ROCHE PALO ALTO LLC (US) 2013-02-12 US disclosed
US-20110028502-A1 DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS BROTHERTON-PLEISS CHRISTINE E 2011-02-03 US disclosed
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS P2RY1, P2RX3, P2RX1 EGFR 3986/4885SRC 3505/4885NPC1 2568/4885
US-20110028502-A1 DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS P2RY1, P2RX7, P2RX3 EGFR 3356/4885SRC 2743/4885NPC1 2814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.